-
Confirmatory clinical failure, K-drug urothelial cancer is not withdrawn and corrected in the first line
Time of Update: 2021-10-02
This is the start of the FDA's "industry acceleration Since the approval of the major review," the first PD-1 drug that has failed to pass the confirmatory clinical trial and is still on sale for indications that has not been revoked but has been converted .
-
Poseida announces positive preliminary results of its CAR-T treatment for prostate cancer
Time of Update: 2021-10-02
Click on the picture and sign up now September 2021 2nd/MedClub News/--Poseida Therapeutics, a clinical-stage biopharmaceutical company, recently announced its autologous CAR-T product P-PSMA-101 for the treatment of metastatic castration-resistant prostate cancer.
-
Turning the "gland" into barbarians, showing its strength, apatamide escorts NM-CRPC patients
Time of Update: 2021-10-02
*Only for medical professionals to read the reference introduction. Advanced prostate cancer innovative drug "apatamide" is China's first and only new androgen receptor approved for "all types" of m
-
Case sharing Abiraterone original research drug vs. generic drug, which one is better?
Time of Update: 2021-10-02
From the analysis of clinical efficacy data, LATITUDE study 1 confirmed that compared with the control group, Abiraterone combined with prednisone + androgen deprivation therapy (ADT) prolonged The time from mHSPC patients to PSA progression was 4.
-
Professor Xing Jinchun and Professor Shi Benkang: Ingenious radioligand therapy illuminates the life of patients with advanced prostate cancer
Time of Update: 2021-10-02
The results of the VISION study showed that 177Lu-PSMA-617 combined with standard treatment prolonged the median overall survival (OS) of patients by 4 months, reduced the risk of death by 38%, and the median imaging progression-free survival (rPFS) was significantly prolonged (8.
-
For the treatment of prostate cancer, the established oncolytic virus company promotes the entry of genetically modified adenovirus drugs into the third phase of clinical medicine. Mai Meng broke the news
Time of Update: 2021-10-02
This clinical trial aims to evaluate the therapeutic effect of CAN-2409 in combination with valacyclovir and standard-of-care radiotherapy alone in the treatment of patients with newly diagnosed localized prostate cancer with intermediate and high risk of recurrence .
-
Long-term constipation and rectal ulcer are actually related to syphilis, Fudan Zhongshan Hospital team BMJ published a case
Time of Update: 2021-10-02
(Screenshot source: Reference [1]) The diagnosis was confirmed by toluidine red unheated serological test and Treponema pallidum particle agglutination test, and the patient was diagnosed with Syphilitic chancre of the rectum .
-
[Subversion] Studies have shown that patients with bladder cancer with mutations in the FGFR3 gene can still benefit from immunotherapy
Time of Update: 2021-10-02
A new study shows that patients with advanced bladder cancer whose tumors have a mutated FGFR3 gene are treated by immunotherapy The response is similar to that of patients without the mutation, a finding that runs counter to the previous hypothesis .
-
Select the power of "Ze" to talk to Professor Zhou Fangjian: Popularize the MDT diagnosis and treatment model, and apply Abiraterone to improve the survival of prostate cancer patients
Time of Update: 2021-10-02
The Medical Oncology Channel specially invited Professor Zhou Fangjian, the leader of the Department of Urology, Sun Yat-sen University Cancer Center, to share on the exploration and future development of prostate cancer MDT model, the use and experience of new endocrine therapy and other topics .
-
CKD patients found that the urine turned purple, but was misdiagnosed as hematuria
Time of Update: 2021-10-02
In August 2021, a doctor at the Yarmouk University School of Medicine in Jordan found that an 80-year-old woman with type 2 diabetes, chronic kidney disease (CKD) stage 5, hypertension, and ischemic stroke had a purple urine bag.
-
NEJM MRI targeted biopsy reduces overdiagnosis and treatment, while still effectively detecting prostate cancer
Time of Update: 2021-10-02
The results of this study indicate that in a population-based screening test, patients with elevated PSA levels and MRI results suggesting that prostate cancer undergoes targeted and standard biopsy are not inferior to standard biopsy in detecting clinically significant prostate cancer.
-
Literature sharing∣UroVysion fluorescence in situ hybridization of urothelial carcinoma: review and future prospects
Time of Update: 2021-10-02
In a prospective follow-up study of patients with low-grade non-muscular invasive BCa, comparing different urine biomarkers, UroVysion is more sensitive and specific than cytology .
reported that compared with cytology and UroVysion, urine DNA methylation can improve the sensitivity of detection of low-grade and early-stage BCa .
-
New hope: immunotherapy helps preserve muscular layer of bladder invasive bladder cancer
Time of Update: 2021-10-02
The researchers conducted a phase II study to explore the efficacy and safety of pembrolizumab + gemcitabine (Gem) + simultaneous hypofractionated radiotherapy (RT) for muscularis sparing invasive bladder cancer (MIBC) .
-
[2021 EAU] The latest progress of PSMA in the diagnosis and treatment of prostate cancer
Time of Update: 2021-10-02
Research methods: retrospectively enrolled 1639 patients with biochemical recurrence (BCR) from 6 centers to evaluate the detection rate of PSMA-PET; use multivariate logistic regression model to evaluate predictive factors; use the coefficients of the original study's Nomoline chart Perform verification (Figure 1) .
-
What is the healthiest frequency of sex?
Time of Update: 2021-10-02
This study uses a lot of data to prove that active sexual activity (more frequent ejaculation) in adult men may reduce the risk of prostate cancer (PCa) .
-
Real-world data comparison: the efficacy of enzalutamide and abiraterone acetate in the treatment of mCRPC
Time of Update: 2021-10-01
In this context, this study compared the baseline characteristics, efficacy, and survival time of enzalutamide and abiraterone acetate in mCRPC patients, and analyzed the effects on imaging progression-free survival (rPFS) and overall survival ( OS) prognostic factors .
-
Zhong Wenwen, Qiu Jianguang, Sun Yat-sen University, etc.: Long non-coding RNA and copy number variation association analysis to identify and verify the prognostic markers of bladder cancer lncRNA
Time of Update: 2021-10-01
Content Introduction Chinese Abstract: Objective: To investigate the role of long non-coding RNAs (LncRNAs) with copy number variation (CNV) in bladder cancer .
Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer[J].
-
Express "first-in-class" new target!
Time of Update: 2021-10-01
▎The content team editor of WuXi AppTec today, Trigone Pharma announced that it has reached a strategic cooperation agreement with 4C Biomed to develop a new type of intravesical immunotherapy .
"Reference: [1] Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer.
-
[Said Wen Jie Mi] 2021 ESMO Urinary Tumor Immunotherapy Hot Spots First Look
Time of Update: 2021-10-01
3. [666P] KEYNOTE-427 study: Pembrolizumab (pembro) single-agent first-line treatment of patients with advanced renal clear cell carcinoma (ccRCC) 41-month follow-up results: Cohort A In recent years, multiple advanced RCC combined treatment studies The efficacy of anti-PD-1 and anti-PD-L1 monoclonal antibodies as first-line therapy has been evaluated, but the data on first-line immune monotherapy is still relatively limited .
-
【Explanation】From simple taste to ascendant: Analysis of the development trend of prostate cancer immunotherapy
Time of Update: 2021-10-01
Cohort B included mCRPC patients who had not undergone chemotherapy, were undergoing androgen deprivation treatment, and had received up to two new anti-androgen therapies in the past to evaluate the efficacy and safety of nivolumab + docetaxel .
